Wednesday, April 30, 2014

Non-Coeliac Gluten Sensitivity – A Scientific Update

Grains & Legumes Nutrition Council
Written by Jessica Biesiekierski

The avoidance of wheat- and gluten-containing products is a worldwide phenomenon, where more than one million Australians purchase gluten-free products for health reasons.1 The Australian gluten-free market is growing up to 20% annually1 and in the USA, it is suggested that as high as 8% of the population purchase gluten- and wheat-free products.2 While coeliac disease is a well-established entity, the evidence-base for gluten as a trigger of symptoms in patients without coeliac disease is minimal (so-called ‘non-coeliac gluten sensitivity’; NCGS). Gluten has been putatively linked to a wide range of conditions including various skin problems,3 fatigue and migraine,4 weight gain5 and autism,6 but most often blamed for gastrointestinal (GI) symptoms.7 Recent data has suggested NCGS may exist, however much remains unknown and important considerations are required before diagnosis. This update discusses the latest scientific evidence in our current understanding of NCGS.

The most well understood gluten intolerance is coeliac disease, an autoimmune GI disease estimated to affect 1% or more of Western populations.8 It occurs when genetically susceptible patients are exposed to dietary gluten, the major protein in wheat, rye, barley and related grains, activating a specific immune response. This leads to small intestinal villous atrophy, intraepithelial lymphocytosis and the development of GI symptoms.9 The only known treatment is a lifelong, strict gluten-free diet (GFD).

Many of the GI symptoms seen in coeliac disease (such as diarrhoea, abdominal pain, bloating, wind, distension and altered bowel habit) can mimic irritable bowel syndrome (IBS). IBS is a disorder characterised by GI symptoms but with no abnormal pathology and affects 15% of the population.10

There is an emerging belief that gluten sensitivity might mediate IBS symptoms.11 Until recently, there were no controlled clinical studies investigating NCGS and the scientific evidence assessing the effects of gluten outside of coeliac disease had focused on animal models or cancer cell lines.12,13 Regardless, the GFD is increasingly prescribed by alternative health practitioners and recommended on Internet sites.

Is it really gluten?
Other components of wheat have been studied in detail, such as the carbohydrate or more specifically, the fructan component.14 Fructans are one of a group of short-chain carbohydrates poorly absorbed in the small intestine. The poor absorption, by virtue of their small molecular size and rapid fermentability, increases delivery of water and fermentable substrates to the colon.15,16 These effects result in increased gas production and GI symptoms in patients with IBS.16-18 This group have been termed FODMAPs, which stands for Fermentable Oligo-, Di-, and Mono-saccharides And Polyols.19 A diet low in FODMAPs has become a well-understood and evidence-based strategy, leading to symptomatic improvement in 70 to 74% of patients with IBS.17,20,21

FODMAPs are found in a wide variety of foods and include lactose (in milk), excess fructose (in pears, apples), fructans and fructo-oligosaccharides (FOS; in artichoke, garlic, onions, wheat and rye), galacto-oligosaccharides (GOS; stachyose and raffinose in legumes), and sugar polyols (sorbitol and mannitol in stone fruits and artificial sweeteners).22,23 Recent grain and cereal composition data has highlighted that wheat- and rye-derived products contain the highest FODMAP content, predominantly fructans and GOS.24 Cereal products with the lowest FODMAP contents are mostly gluten-free, based on rice, oat, quinoa and corn ingredients.24 Therefore, choosing ‘gluten-free’ products is likely to result in automatically selecting a low-FODMAP diet.

What is so wrong with being gluten-free?
Exclusion of coeliac disease – The prescription of a GFD for gut and other symptoms may lead to the under diagnosis of coeliac disease. Two in three patients with self-perceived NCGS do not have coeliac disease adequately excluded,25 which increases patients’ risk of inadequate management and screening of associated complications if left untreated (i.e., reduced bone health,26 long-term mortality27).

Nutritional concerns – The GFD is markedly restrictive, presents challenges when eating at places other than home and can be two to three times more expensive than that of a standard diet.28 It can also be nutritionally inadequate, especially in fiber and B-vitamins.29 In addition, at least 45% of patients with self-perceived NCGS self-initiate the GFD and have not undergone dietetic education to ensure maintained nutritional adequacy.25 Long-term restrictive diets, particularly avoidance of wheat- and gluten-based products, are likely to have health implications given their important role in bowel health.

What is the current evidence behind NCGS?
Evaluation of exclusion diets has previously shown wheat-induced gut symptoms,30 but given wheat is also high in fructans, such evidence for NCGS has been inconclusive. Other studies, mostly completed in animal models31 or uncontrolled clinical trials have found some evidence for the efficacy of a GFD. In these published studies, however, either the patients have had coeliac-associated antibodies or intraepithelial lymphocytosis in the duodenum32,33 and, therefore, have not been convincingly defined as NCGS.

The first definitive experiment where the effect of gluten, free from contamination from carbohydrates, was evaluated in patients with IBS where coeliac disease had been definitively excluded was published in 2011.34 This study was a randomised double-blind, placebo-controlled trial of a single dose of gluten (16 g/day for 6 wk) without a controlled background in parallel groups (n=34). The results showed gluten specifically induced GI symptoms and tiredness in those who have NCGS. Although these results were exciting, they must be reproduced to confirm the existence of NCGS.

The same research group went onto conduct another dietary trial using a crossover design and supplying a controlled diet.35 Following a 2-week run-in period on a low FODMAP diet, 40 patients with NCGS and IBS who were symptomatically controlled on a GFD underwent a double-blind, placebo-controlled, randomised crossover trial of placebo, low-gluten (2g/day) or high-gluten (16g/day) for 1 week, followed by a 2-week washout period, before crossing over to the next diet. Protein levels were balanced with whey protein. No evidence of specific or dose-dependent effects of gluten was observed, but FODMAP restriction uniformly reduced residual symptoms. There were no changes in markers of potential mechanism including intestinal inflammation/injury, immune activation or by-products of protein metabolism.

A separate gluten (16g/day) and whey (16g/day) re-challenge in 22 of these patients showed poor reproducibility of symptom induction to a specific protein. A very high placebo response was found in both trials, regardless of all background dietary triggers being controlled. Either the patients do not have NCGS as self-reported or the trial design precluded its recognition. A better understanding is warranted for the diagnosis of NCGS where self-reporting is probably inaccurate.

Future research directions for NCGS
Current research is focusing on non-GI symptoms reported to improve with the GFD and continues to investigate the effects of gluten on intestinal inflammation, permeability, and other pathways of both innate and adaptive immunity in patients who do not have coeliac disease.

How common NCGS is, how it can be reliably identified and what its underlying mechanisms are, warrant further evaluation. Without convincing results showing effects on inflammatory or immune markers, NCGS should be regarded as a sub-group of IBS and distinct from coeliac disease.

Concluding comments
We have some evidence for the existence of NCGS, but this group remains poorly understood. We have no evidence to allow a plausible explanation of the pathogenesis of NCGS and more definitive research is needed to fulfill our understanding. Although the use of dietary gluten restriction in the management of patients with functional gut symptoms may benefit a small number of people, lowering the dietary intake of FODMAPs continues to be the first line therapy for IBS. Conducting well-controlled dietary studies are complex; the most valid study design of verifying the existence of NCGS remains unsubstantiated. Public health agencies and the food industry must not perpetuate public demand and consumer trends for the GFD without sufficient evidence first supporting the existence of NCGS.

Identifying patients with NCGS
Medical advice and dietetic supervision (ideally someone trained in the low FODMAP dietary method) is imperative throughout this process.

Key messages: 

  • Self-reported NCGS and improved symptoms on a GFD may not be an accurate indication of the condition
  • Prevalence and diagnostic procedures including biomarkers are not yet clearly defined
  • Widespread promotion of GFD to treat gluten intolerance without first excluding coeliac disease may lead to coeliac disease not being detected and increase the risk of related consequences
  • Lowering the dietary intake of FODMAPs continues to be first line therapy for managing GI symptoms
  • Recommend referral of patients to a specialist dietitian


  1. Vinning G, McMahon G. Gluten-free Grains: A demand-and-supply analysis of prospects for the Australian grains industry. Canberra, Australia: Rural Industries Research and Development Corporation, Australian Government, 2006
  2. Cromley J. Going gluten-free -- for many reasons. Los Angeles Times. California, USA, 2008.
  3. Fry L. Dermatitis herpetiformis. Oxford, UK: Blackwell Scientific Publications, 1992.
  4. Hadjivassiliou M et al. Gluten sensitivity as a neurological illness. J Neurol Neurosurg Psychiatry 2002;72:560-563.
  5. Dickey W, Kearney N. Overweight in celiac disease: Prevalence, clinical characteristics, and effect of a gluten-free diet. Am J Gastoenterol 2006;101:2356-2359.
  6. Lucarelli S et al. Food allergy and infantile autism. Panminerva Medica 1995;37:137-141.
  7. Hadley SK, Gaarder SM. Treatment of irritable bowel syndrome. Am Fam Physician 2005;72:2501-6.
  8. Dube C et al. The prevalence of celiac disease in average-risk and at-risk Western European populations: a systematic review. Gastroenterology 2005;128:57-67.
  9. Shan L et al. Structural basis for gluten intolerance in celiac sprue. Science 2002;297:2275-2279.
  10. Markowitz MA et al. IBS prevalence: results from a community based patient registry based on the Rome II criteria. The American journal of gastroenterology 2000;95:2634-2634.
  11. Cash BD et al. The prevalence of celiac disease among patients with nonconstipated irritable bowel syndrome is similar to controls. Gastroenterology 2011;141:1187-93.
  12. Sander GR et al. Rapid disruption of intestinal barrier function by gliadin involves altered expression of apical junctional proteins. FEBS Letters 2005;579:4851-4855.
  13. Giovannini C et al. Induction of apoptosis in Caco-2 cells by wheat gliadin peptides. Toxicology 2000;145:63-71.
  14. Roberfroid MB, Delzenne NM. Dietary fructans. Annu Rev Nutr 1998;18:117-143.
  15. Barrett JS et al. Dietary poorly absorbed, short-chain carbohydrates increase delivery of water and fermentable substrates to the proximal colon. Aliment Pharmacol Ther 2010;31:874-82.
  16. Ong DK et al. Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome. J Gastroenterol Hepatol 2010;25:1366-73.
  17. Shepherd SJ et al. Dietary triggers of abdominal symptoms in patients with irritable bowel syndrome: randomized placebo-controlled evidence. Clin Gastroenterol Hepatol 2008;6:765-71.
  18. Rumessen JJ, and Gudmand-Hoyer, E. Fructans of chicory: intestinal transport and fermentation of different chain lengths and relation to fructose and sorbitol malabsorption. American Journal of Clinical Nutrition 1998;68:357-64.
  19. Shepherd SJ, Gibson PR. Fructose malabsorption and mymptoms of irritable bowel syndrome: guidelines for effective dietary management. J Am Diet Assoc 2006;106:1631-1639.
  20. Gibson PR, Shepherd SJ. Food choice as a key management strategy for functional gastrointestinal symptoms. Am J Gastroenterol 2012;107:657-66.
  21. Halmos EP et al. A Diet Low in FODMAPs Reduces Symptoms of Irritable Bowel Syndrome. Gastroenterology 2014;146:67-75.e5.
  22. Muir JG et al. Measurement of short-chain carbohydrates in common Australian vegetables and fruits by high-performance liquid chromatography (HPLC). J Agric Food Chem 2009;57:554-565.
  23. Muir JG et al. Fructan and free fructose content of common Australian vegetables and fruit. J Agric Food Chem 2007;55:6619-27.
  24. Biesiekierski JR et al. Quantification of fructans, galacto-oligosacharides and other short-chain carbohydrates in processed grains and cereals. J Hum Nutr Diet 2011.
  25. Biesiekierski JR et al. Characterization of adults with a self-diagnosis of non-celiac gluten sensitivity. Nutrition in Clinical Practice 2014;Accepted 02 March 2014.
  26. Godfrey JD et al. Morbidity and mortality among older individuals with undiagnosed celiac disease. Gastroenterology 2010;139:763-9.
  27. Rubio-Tapia A et al. Increased prevalence and mortality in undiagnosed celiac disease. Gastroenterology 2009;137:88-93.
  28. Lee AR et al. Economic burden of a gluten-free diet. J Am Diet Assoc 2007;20:423-430.
  29. Thompson T et al. Gluten-free diet survey: Are Americans with celiac disease consuming recommended amounts of fibre, iron, calcium and grain foods? J Hum Nutr Diet 2005;18:163-169.
  30. Jones VA. Food intolerance: A major factor in the pathogenesis of irritable bowel syndrome. Lancet 1982;2:1115-1117.
  31. Verdu EF et al. Gliadin-dependent neuromuscular and epithelial secretory responses in gluten-sensitive HLA-DQ8 transgenic mice. Am J Physiol Gastrointest Liver Physiol 2008;294:G217-25.
  32. Wahnschaffe U et al. Celiac disease-like abnormalities in a subgroup of patients with irritable bowel syndrome. Gastroenterology 2001;121:1329-1338.
  33. Wahnschaffe U et al. Predictors of clinical response to gluten-free diet in patients diagnosed with diarrhea-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol 2007;5:844-850.
  34. Biesiekierski JR et al. Gluten causes gastrointestinal symptoms in subjects without celiac disease: a double-blind randomized placebo-controlled trial. Am J Gastroenterol 2011;106:508-14.
  35. Biesiekierski JR et al. No effects of gluten in patients with self-reported non-celiac gluten sensitivity after dietary reduction of fermentable, poorly absorbed, short-chain carbohydrates. Gastroenterology 2013;145:320-328 e3.